From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
 | Baseline | 6 months | 12 months | 18 months | |
---|---|---|---|---|---|
% of patients on low/standard/high dose CAN, number# of patients analysed (N) | 4/77/19, N=47 | 31/41/28, N=32 | 42/27/31, N=26 | 36/36/28, N=14 | |
 | PGA absent/mild-moderate/severe | ||||
Physician Global Assessment (PGA), %# of patients | lower than SD* CAN | 54/23/15 | 80/10/0 | 78/22/0 | 80/20/0 |
SD* CAN | 42/50/0 | 88/12/0 | 50/33/0 | 50/25/0 | |
higher than SD* CAN | 20/60/20 | 33/67/0 | 0/67/0 | 0/100/0 | |
 | VAS 0–10, (min; max) | ||||
Patients' assessment of current disease activity (median) | lower than SD* CAN | 1 (0; 9) | 1 (0; 7) | 1 (0; 4) | 2 (0; 3) |
SD* CAN | 2 (0; 10) | 3 (0; 7) | 3 (0; 10) | 4 (0; 10) | |
higher than SD* CAN | 4 (1; 5) | 3 (0; 6) | 3 (1; 5) | 4 (1; 6) |